IRD (32) FULC (40) BNTC (37) GLSI (41) ⌘ Pro Terminal →

Vogenx Inc (VOGX) — RQD Stock Rating Cockpit

$19.92 +5.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Vogenx Inc (VOGX) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $295.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VOGX)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

52.930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE27% OF RANGE

L: $13$19.92H: $38

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on VOGX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (55)

20/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like VOGX

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VOGX)

✓Walkthrough of VOGX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VOGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +53.23%📐 HORIZONTAL RANGE

2026-10-30O $19.63H $20.74L $19.24C $19.92VOL 45.1K

RES: $43.55SUP: $4.82SMA50: $24.68SMA200: $23.83

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VOGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VOGX Butterfly Map → + Track VOGX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VOGX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VOGX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VOGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VOGX)

Health Care Rank #267 of 1016 ⚔️ IRD vs VOGX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VOGX vs. IRD, FULC, BNTC, GLSI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Vogenx Inc (VOGX) ranks #267 by composite RQD confidence (56/100, grade D+) and #519 by equity capitalization ($295.9M). Within this direct 5-issuer industry benchmark cohort, VOGX leads on earnings valuation at N/A trailing P/E, while IRD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. VOGX currently leads its immediate peer cohort in composite quantitative strength at 56/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VOGX ACTIVE Vogenx Inc	D+	56/100	—	—	—	+5.29%	$295.9M	Benchmark Subject
IRD Opus Genetics Inc.	E	32/100	—	—	-35.0%	-0.81%	$303.7M	/ird-vs-vogx →
FULC Fulcrum Therapeutics Inc.	D-	40/100	—	—	-35.0%	+0.53%	$288.0M	/fulc-vs-vogx →
BNTC Benitec Biopharma Inc.	D-	37/100	—	—	-35.0%	+0.34%	$308.1M	/bntc-vs-vogx →
GLSI Greenwich LifeSciences Inc.	D-	41/100	—	—	-35.0%	+3.77%	$278.9M	/glsi-vs-vogx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001903784

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vogenx Inc (VOGX) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, VOGX closed FY2025 with $681.2K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$681.2K	—

3. VOGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VOGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Vogenx Inc (NASDAQ: VOGX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $19.92 (+5.29% 1D, market cap $295.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, VOGX ranks #267 in composite RQD confidence.

How does VOGX compare to IRD and FULC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VOGX carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IRD (Opus Genetics Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $303.7M) and FULC (Fulcrum Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $288.0M). Among the 5-stock peer group, VOGX leads on earnings multiple (N/A) while IRD leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VOGX?

Per VOGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001903784), Vogenx Inc generated $0 in revenue, $0 in net income, and $0 in free cash flow against $681.2K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VOGX trading relative to its 50-day, 200-day, and 52-week technical levels?

VOGX last traded at $19.92 (+5.29% on volume of 75,381 shares), positioning the stock -19.29% below its 50-day simple moving average ($24.68) and -16.41% below its 200-day simple moving average ($23.83). Across its 52-week range of $12.95 to $38.41, VOGX sits at the 27.4% percentile with a 14-day RSI of 52.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($17.43 to $22.41).

VOGX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell VOGX stock right now?

Vogenx Inc (VOGX) currently earns a Roarable Rating of D+ (Sell — SELL) with 56/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is VOGX's 12-month price target and RQD AI Jury consensus?

VOGX's 12-month base price target is $19.74 (range $15.4 to $40.33), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: VOGX RQD Cockpit VOGX 12M Forecast VOGX Earnings & Move VOGX Dividends & DRIP VOGX Insiders & 13F VOGX Whale Options VOGX Profit Sankey VOGX News & Why